Creating synthetic proteins to inhibit disease-related interactions
Biomolecular Recognition with Synthetic Protein Mimics
['FUNDING_OTHER'] · NEW YORK UNIVERSITY · NIH-11051887
This study is exploring how to create new types of proteins that can block harmful interactions between proteins in the body, especially those that are tricky to target, to help develop better treatments for diseases.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NEW YORK UNIVERSITY (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11051887 on ClinicalTrials.gov |
What this research studies
This research investigates how synthetic protein mimics can be designed to interfere with harmful protein interactions that lead to diseases. By mimicking the small folded domains of proteins, the researchers aim to create molecules that can specifically inhibit the formation of problematic protein complexes. The focus is on targeting intrinsically disordered proteins (IDPs), which play critical roles in various cellular processes but are challenging to target with traditional methods. The goal is to develop new therapeutic strategies that can effectively engage these proteins and disrupt their interactions with other biomolecules.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with conditions linked to dysfunctional protein interactions, particularly those involving intrinsically disordered proteins.
Not a fit: Patients with diseases not related to protein interactions or those whose conditions do not involve intrinsically disordered proteins may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments for diseases caused by misregulated protein interactions.
How similar studies have performed: While targeting intrinsically disordered proteins is a relatively novel approach, there have been some promising advancements in similar strategies for protein interaction modulation.
Where this research is happening
NEW YORK, UNITED STATES
- NEW YORK UNIVERSITY — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ARORA, PARAMJIT S — NEW YORK UNIVERSITY
- Study coordinator: ARORA, PARAMJIT S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.